Search results for: 'data mitigation solutions q2 2025'

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) ...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

02 Sep 2025  |  Global  |  Technology Research

Technological Advances in Engineered Cell Therapies, Global, 2025–2029

Emerging Trends and Technologies in Engineered Cell Therapies

Infographics

×

Engineered cell therapies have become a revolutionary medical field, surpassing conventional methods such as systemic medications and prominent immunosuppression to provide long-lasting, programmable, and targeted treatments for complicated diseases. Recent technical developments in engineered cell therapies examine how the rapid growth of cell eng...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The pharmaceutical and biotechnology industries are entering a transformative era in 2025, shaped by a convergence of scientific innovation, regulatory evolution, and market pressures. One of the key imperatives is the continued advancement of therapeutics and drug approvals, as breakthrough treatments, particularly in personalized medicine, promis...

In this analysis, Frost & Sullivan identifies and defines the leading trends shaping the global pharmaceutical landscape. The study period is 2022–2030, with 2024 as the base year and 2025–2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and th...

09 May 2025  |  Global  |  Technology Research

Emerging Anti-aging strategies

Evolving Anti-aging Strategies Are Driving Transformational Growth in Innovation, Market Players, and Emerging Opportunities

Infographics

×

This report delves into the rapidly evolving anti-aging industry, highlighting the breakthrough innovations in cellular and genomic rejuvenation as well as AI/ML-driven anti-aging strategies. It explores the industry ecosystem, covering key players, emerging players, and academic researchers transforming the field. The analysis includes major techn...

The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and environmental factors, requiring personalized therapeut...